Excelsior Medical Co., Ltd. (TPE:4104)
72.90
-0.40 (-0.55%)
Oct 30, 2026, 1:30 PM CST
Excelsior Medical Revenue
Excelsior Medical had revenue of 2.39B TWD in the quarter ending June 30, 2026, with 10.08% growth. This brings the company's total for the last twelve months to 9.20B, up 6.33% year-over-year. In the year 2025, Excelsior Medical had annual revenue of 8.79B with 2.94% growth. That makes Excelsior Medical the 14,951st largest company in the world by revenue and 479th in Taiwan.
Revenue (ttm)
9.20B
Revenue Growth
+6.33%
P/S Ratio
1.49
Revenue / Employee
66.68M
Employees
138
Market Cap
13.73B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Excelsior Medical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.79B | 250.69M | 2.94% |
| Dec 31, 2024 | 8.54B | 305.14M | 3.71% |
| Dec 31, 2023 | 8.23B | 1.05B | 14.56% |
| Dec 31, 2022 | 7.19B | 613.68M | 9.34% |
| Dec 31, 2021 | 6.57B | -102.34M | -1.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| TaiDoc Technology | 4.23B |
| EirGenix | 1.21B |
| Ever Supreme Bio Technology | 1.08B |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 42.22M |
| AP Biosciences | 32.25M |
| Caliway Biopharmaceuticals | 29.39M |